Drug interactions can lead to adverse reactions Villages Daily Sun, FL - Depending on the combination, adverse reactions can include depression, bleeding, confusion, constipation, urine retention and dangerously low blood ...
Smoking drug has psychiatric side effects 6minutes, Australia - In the latest Australian Adverse Drug Reactions Bulletin clinicians are advised to be vigilant for neuropsychiatric effects in patients using varenicline, ...
GMDAT?s Grimaldi Pins Hopes on New Lacetti-Cruze, Beat Minicar Ward's Auto (subscription), MI - The Lacetti Premiere?s launch has gone well, despite the adverse conditions, he says. Serial production started this month, and GMDAT had 4000 orders in the ...
Recent News and Articles on the Keywords: pharmacogenetics + web + 35,900 Related to the article below (Last Update: 8/7/2008)
Transgenomic Reports Second Quarter 2008 Results MarketWatch - Aug 5, 2008 The Company provides products and services in the fields of pharmacogenomics and pharmacogenetics. Product offerings include the WAVE(R) DHPLC Systems and ...OTC:TBIO
PharmGKB: the Pharmacogenetics Knowledge Base - M Hewett, DE Oliver, DL Rubin, KL Easton, JM … - Nucleic Acids Research, 2002 - Oxford Univ Press ... Researchers in the Pharmacogenetics Research Network are studying a variety of ... the
relationships between the ontological terms form a rich web of information. ...
[PDF]Indexing pharmacogenetic knowledge on the World Wide Web - RB Altman, DA Flockhart, ST Sherry, DE Oliver, DL … - Pharmacogenetics, 2003 - smi-web.stanford.edu ... However, in order to accelerate public participation and guidance in our efforts,
we have created a web site where the pharmacogenetics community can specify ... -
PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base - TE Klein, RB Altman - The Pharmacogenomics Journal, 2004 - nature.com ... PharmGKB, http://www.pharmgkb.org) is a public repository of genotype and phenotype
information relevant to pharmacogenetics. The PharmGKB is web-based and ...
Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency - MW Linder, RA Prough, R Valdes Jr - Clinical Chemistry, 1997 - Am Assoc Clin Chem ... Review. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
Mark W. Linder 1 , Russell A. Prough 2 and Roland Valdes, Jr. 1 ,2 ,a ...
Pharmacogenetics of Warfarin Elimination and its Clinical Implications. - H Takahashi, H Echizen - Clinical Pharmacokinetics, 2001 - pharmacokinetics.adisonline.com ... In this context, we discuss the pharmacogenetics of warfarin elimination and its
clinical ... ie, from CYP2C9*6 to CYP2C9*12) are registered at the web site of the ...
Pharmacogenomics-it's not just pharmacogenetics - DS Bailey, A Bondar, LM Furness - Current Opinion in Biotechnology, 1998 - Elsevier Page 1. 595 Pharmacogenomics - it's not just pharmacogenetics...Pharmacogenetics: linking
drug response to individual genetic variation In a second iteration. ...
Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms - D Otterness, C Szumlanski, L Lennard, B Klemetsdal … - Clinical Pharmacology & Therapeutics, 1997 - nature.com Clinical Pharmacology & Therapeutics (1997) 62, 60?73; doi: Human thiopurine
methyltransferase pharmacogenetics: Gene sequence polymorphisms *. ...
Source: Google Scholar
Pharmacogenetics could reduce the incidence of adverse reactions and optimize treatments
Researchers, at Washington University School of Medicine in St. Louis and the St. Louis College of Pharmacy, found that 29 percent of patients seen at local primary-care offices had taken at least one of 16 drugs that can cause adverse reactions in genetically susceptible people.
Applying information from pharmacogenetics to primary-care practices could reduce the incidence of adverse reactions and optimize treatments, according to the study, published in the journal Pharmacogenomics.
" Until now, researchers looking at the role of genetic variation in drug effects have focused mainly on toxic drugs used by specialists treating cancer or HIV infection," says Howard L. McLeod, at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital.
" We knew that some of the drugs commonly used in the family practice setting can cause adverse reactions in people who have certain genetic variations, so we measured just how often these drugs are used."
The study found that of the 607 outpatients surveyed at three primary-care sites in the metropolitan St. Louis area, 174 were on a drug commonly associated with severe side effects. Among these drugs are Fluoxetine ( Prozac ), Metoprolol ( a beta-blocker ), Diltiazem ( a calcium channel blocker ), and Warfarin ( an anticoagulant ).
Each of these drugs is metabolized by genes known to vary within the population. Genetic variations that change the properties of enzymes that break down drugs or mark them for excretion can cause adverse drug reactions.
Potentially harmful reactions to the medications examined in this study include gastrointestinal bleeding, cerebrovascular hemorrhages, kidney impairment, dizziness, low blood pressure and slowed heart beat. The number and severity of adverse reactions to the drugs surveyed was not measured in this study; however, a 1998 study ranked adverse drug reactions as among the top ten leading causes of death in the United States.
Other genetic variations in the population are known to alter proteins that transport drugs or change cellular mechanisms targeted by drugs, rendering the drugs ineffective. While not leading to adverse reactions, these genetic factors can also affect health care.
" We think it's likely that using pharmacogenetics in the primary-care setting can reduce health care costs," says McLeod. " The information could help family physicians make better decisions about the right drugs and dosages to prescribe for their patients, making it possible to avoid unnecessary prescriptions and to minimize the costs of hospital treatments for adverse reactions."
Source: Washington University School of Medicine, 2006